German biotechnology company BioNTech on Monday announced plans to expand its global footprint to Asia by building its first mRNA manufacturing facility in Singapore.
The Covid vaccine maker will establish its regional headquarters for Southeast Asia in Singapore, later this year, it said in a statement. The facility will be operational as early as 2023, it added.
The fully integrated mRNA manufacturing facility will provide regional and global supply capacity of BioNTech’s growing pipeline of mRNA-based product candidates. It will be equipped to produce a range of novel mRNA vaccines and therapeutics for infectious diseases and cancer.
